Appointment of Chief Operating Officer
Accomplished technology executive and innovator Dr. Niko Pagoulatos joins Spectral MD
LONDON, U.K AND DALLAS, TX, U.S. – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for rapid and accurate treatment decisions in wound care, announces the appointment of Dr. Niko Pagoulatos as Chief Operating Officer, effective this week.
As Chief Operating Officer of Spectral MD, reporting to CEO Wensheng Fan, Dr. Pagoulatos will accelerate growth and operational performance of the Company with specific focus on scientific research, engineering, product development leading to global portfolio launch and clinical adoption.
Dr. Pagoulatos comes to Spectral MD as an accomplished technology executive and innovator with 25+ years of experience in engineering, clinical and business aspects of specialized medical ultrasound imaging. Dr. Pagoulatos is a team-oriented and results-driven leader with extensive experience and a strong track record in building and leading cross-functional teams to successfully commercialize innovative medical technologies with global clinical impact.
Dr. Pagoulatos has held multiple executive roles including Chief Innovation Officer, Chief Operating Officer, and most recently, Chief Technology Officer at EchoNous, a global healthcare innovation company headquartered in Seattle focused on the development and commercialization of the first AI-assisted handheld ultrasound tool to increase diagnostic confidence at the bedside.
Dr. Pagoulatos earned his B.S. in Physics from the University of Athens in Greece and completed his graduate studies at the University of Washington in Seattle, where he earned a M.S. in Bioengineering in addition to a M.S. and Ph.D. in Electrical Engineering.
Niko Pagoulatos, Chief Operating Officer of Spectral MD, said: “I am impressed with Spectral MD’s wound healing assessment breakthrough technology, and I am excited to join its world-class team. I look forward to applying my experience and expertise to help Spectral MD build on its success, release its breakthrough DeepView™ technology into the market, and execute on its strategic goals to revolutionize wound care management worldwide.”
Wensheng Fan, Chief Executive Officer of Spectral MD, said: “Niko is a transformational leader and proven industry innovator with deep experience in medical ultrasound imaging, product innovation, and groundbreaking AI solutions. As an innovative and seasoned executive, I am confident his broad operational experience will be critically important as we continue to manage our growth, scaleup operations and seek to bring DeepView™ through development and into the market. I am truly delighted to welcome Niko to the Spectral MD team.”
Proactive Investors interview with COO, Niko Pagoulatos
To view the interview click here
For further information please contact:
| Spectral MD Holdings, Ltd. | https://investors.spectralmd.com |
| Wensheng Fan, Chief Executive Officer | via Walbrook PR |
| Wan Lung Eng, Chief Financial Officer | |
| SP Angel Corporate Finance LLP (NOMAD & BROKER) | Tel: +44 (0)20 3470 0470 |
| Stuart Gledhill/Caroline Rowe (Corporate Finance)Vadim Alexandre/Rob Rees (Sales & Broking) | |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com |
| Paul McManus/Sam AllenAlice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7407 804 654 |
Further background on Dr. Pagoulatos
Dr. Pagoulatos comes to Spectral MD as an accomplished technology executive and innovator with 25+ years of experience in engineering, clinical and business aspects of specialized medical ultrasound imaging. Dr. Pagoulatos is a team-oriented and results-driven leader with extensive experience and a strong track record in building and leading cross-functional teams to successfully commercialize innovative medical technologies with global clinical impact. Dr. Pagoulatos invented several breakthrough ultrasound technologies that include key industry-first features and holds authorship on ten patents and multiple scientific publications. Additionally, Dr. Pagoulatos is one of the first researchers in the world to develop algorithms for the real-time fusion of ultrasound and magnetic resonance imaging.
Dr. Pagoulatos has held multiple executive roles including Chief Innovation Officer, Chief Operating Officer, and most recently, Chief Technology Officer at EchoNous, a global healthcare innovation company headquartered in Seattle focused on the development and commercialization of Kosmos, the first AI-assisted handheld ultrasound tool to increase diagnostic confidence at the bedside. In these roles, he shaped the Company’s vision and mission, synthesized global market and clinical data, drove technology development and product roadmaps, as well as managed multimillion-dollar cross-functional team budgets. While at EchoNous, Dr. Pagoulatos built and led a team that developed and released to global markets the innovative handheld ultrasound tool Kosmos, the only AI-driven handheld ultrasound tool benchmarked against cart-based ultrasound systems with several industry-first technologies and features. Dr. Pagoulatos and his team delivered 510(k) clearance and CE mark for Kosmos in four years from company inception and obtained several certifications, including ISO 13485.
Prior to EchoNous, Dr. Pagoulatos held Director and advanced development engineering roles at FUJIFILM SonoSite, the world leader in point-of-care ultrasound (POCUS). During his tenure, Dr. Pagoulatos led the productization and global market release of several innovative products including advanced needle visualization, a well-established ultrasound imaging feature for ultrasound-guided needle procedures in POCUS, and a portable ultrasound device iViz, FUJIFILM Sonosite’s first tablet-form-factor ultrasound system designed for high-mobility. Additionally, Dr. Pagoulatos has held Senior Scientist roles within the Ultrasound Division of Siemens Healthineers and DYSIS Medical. At Siemens, Dr. Pagoulatos led the development and integration of a real-time 3D processing and visualization module into the first 4D ultrasound scanner released by the company. At DYSIS Medical, he developed a spectral imaging registration algorithm and led the software development effort of an innovative dynamic spectral imaging device designed for non-invasive detection of cervical cancer.
Dr. Pagoulatos earned his B.S. in Physics from the University of Athens in Greece and completed his graduate studies at the University of Washington in Seattle, where he earned a M.S. in Bioengineering in addition to a M.S. and Ph.D. in Electrical Engineering.
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown” ® with our DeepView™ Imaging System.